Blood test biomarker to help preserve organs in rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have confirmed rectal adenocarcinoma that is stage II or III (tumors like T3N0M0 through T4bN2M0)
- Provide written consent before any study-specific tests or procedures
- No signs of spread to distant organs on imaging tests at screening
- No prior treatment for your rectal cancer
- No blood transfusion within 1 month of starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
This study uses a special blood test to look for traces of tumor DNA (ctDNA) and compares it with information from your original tumor tissue or a new biopsy. It’s done in people with locally advanced rectal cancer who are going to receive standard chemotherapy and radiation, aiming to better track the cancer’s behavior.
This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.